Family History Red Flags Every Primary Care Provider Should Catch

Most patients with hereditary disease risk go undiagnosed. Not because the risk is rare, but because the family history that would have flagged it never made it onto the chart.

A complete three-generation pedigree takes time most clinic visits do not have. The good news is that you do not need a full pedigree to identify who needs a genetics referral.

You need a short list of red flags that should always trigger one.

Here are ten.

1. Cancer in close relatives diagnosed before age 50

Breast cancer before 50. Colorectal cancer before 50. Prostate cancer before 50. These are well-established NCCN criteria for hereditary cancer evaluation, and they are still the most commonly missed.

If your patient has a first or second-degree relative diagnosed with any of these cancers before 50, refer them for genetic counseling. The patient does not need to be diagnosed themselves.

2. Two or more primary cancers in the same person

A relative with breast cancer at 55 who later developed ovarian cancer at 65. A father with colon cancer and a separate primary in the small bowel. Two unrelated primary cancers in one person, even at older ages, is a hereditary cancer red flag.

3. Specific high-risk cancers at any age

Some cancers warrant genetics evaluation regardless of age at diagnosis or family history. These include:

• Ovarian cancer

• Male breast cancer

• Pancreatic cancer

• Metastatic prostate cancer

• Triple-negative breast cancer diagnosed before age 60

  
  

Per NCCN, a single occurrence of any of these in your patient or a close relative is sufficient indication for testing.

4. Ten or more cumulative adenomatous polyps

A patient who had eight polyps removed across two colonoscopies, then two more this year. Cumulative adenomatous polyp counts of ten or more across a lifetime point to a hereditary polyposis syndrome, including familial adenomatous polyposis (FAP), MUTYH-associated polyposis, and several rarer conditions.

Per NCCN, this threshold should trigger genetics referral regardless of family history. The implications for screening intervals, prophylactic surgery, and family cascade testing are significant.

5. Sudden cardiac death or aortic event before age 60

A father who died of an aortic dissection at 52. A cousin with sudden cardiac death during a basketball game in his 30s. Unexplained sudden cardiac death or aortic dissection in a relative under 60 is a red flag for inherited cardiovascular disease, including hypertrophic cardiomyopathy, dilated cardiomyopathy, ARVC, and vascular Ehlers-Danlos syndrome (vEDS).

These patients benefit from cardiac surveillance that starts decades earlier than population screening would suggest.

6. Joint hypermobility plus vascular or cardiac involvement

Joint hypermobility is common. Joint hypermobility paired with a family history of aortic aneurysm, spontaneous pneumothorax, or unexplained vascular rupture is not. The 2017 International Classification of EDS established clear criteria for genetic evaluation of vEDS, and earlier diagnosis meaningfully changes management and surveillance.

7. Recurrent pregnancy loss or unexplained infertility

Three or more first-trimester losses, or a couple working through unexplained infertility, can point to balanced chromosomal rearrangements in one partner or to carrier states for severe recessive conditions.

Genetic counseling can clarify whether testing is appropriate, what to test, and how to interpret results in the context of family-building decisions. This is also the right point to discuss expanded carrier screening, which is now ACOG-recommended for all reproductive-age patients regardless of ancestry or family history.

8. Early-onset neurodegenerative disease in the family

Dementia before age 65. ALS at any age. Early-onset Parkinson disease. Huntington disease in any generation. These warrant genetic evaluation for both diagnostic clarity in affected relatives and predictive testing decisions for unaffected family members.

Predictive testing in particular benefits from counseling well before any test is ordered. The decision to know or not know a future risk is one of the most carefully studied areas in genetic counseling, and patients deserve a structured conversation before they commit either way.

9. A history of adverse drug reactions or poor medication response

A patient who failed three SSRIs. Someone who needed unusually high doses of opioids after a routine surgery. A patient who developed a severe reaction to a common antibiotic.

Pharmacogenomic testing can identify metabolic differences that explain the pattern and guide future prescribing. This is particularly relevant for patients on long-term psychiatric, cardiovascular, or pain medications. PGx is one of the most underused tools in primary care, and it pays for itself the first time it prevents a months-long medication trial that was never going to work.

10. A known pathogenic variant in the family

If anyone in the family has tested positive for a hereditary disease variant, every blood relative is a candidate for cascade testing. This is the highest-yield genetic testing referral in medicine, and it is routinely missed.

If your patient mentions an aunt with a BRCA variant or a brother with Lynch syndrome, refer them. Cascade testing is also one of the most cost-effective forms of genetic testing per dollar spent.

What we do at Empower Genetics

If any of these situations come up in your clinic, you don't have to figure out the genetic workup on your own. That's what Empower Genetics is here for.

Empower Genetics is a direct-pay telehealth practice based in Idaho, and licensed in multiple states. Most patients are seen within one to two weeks, and we ensure that the referring provider is kept in the loop and is aware of all testing ordered, results, and recommendations for treatment and management.

We do not require a referral, but we welcome them. The simplest way to send someone is to point them to empowergeneticshealth.com or fax records to 208-252-7511.

For your patients: we are direct-pay and provide superbills for HSA, FSA, and out-of-network reimbursement. The reason we work this way is to keep wait times short and visits unhurried, not to make genetic care harder to access.

If a case keeps showing up on your problem list and you do not have the bandwidth to chase it down, send them our way

. We will take it from there.

References: NCCN Guidelines v3.2026 (Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate); NCCN Guidelines (Genetic/Familial High-Risk Assessment: Colorectal); 2017 International Classification of Ehlers-Danlos Syndromes; ACOG Committee Opinion on Carrier Screening; CPIC Guidelines for Pharmacogenomic Testing.